Today the SBIR was reauthorized for a period of 6 years, ending September 30, 2017. This includes STTR, and what was the Commercialization Pilot Program (CPP), now to be known as the Commercialization Readiness Program (CRP). The reauthorization was included in the National Defense Authorization Act of 2012 (NDAA) HR.1540.
The bill has been sent to the President to sign the bill into law, and he has said he would.Continue reading
Technique evaluates heterogeneity of tumors using novel image analysis algorithms with standard immunohistochemistry techniques
Press Release via 2011 AZBio Fast Lane Award winner Flagship Biosciences.Continue reading
Technology Commercialization Assistance now available from the Arizona Commerce Authority
Download the application as a PDF Document
| For Immediate Release: | Wednesday, December 14, 2011 |
| Contact: | CMS Office of Public Affairs 202-690-6145 |
AFFORDABLE CARE ACT SUNSHINE;
RULE INCREASES TRANSPARENCY IN HEALTH CARE
The Centers for Medicare & Medicaid Services (CMS ) announced today a proposed rule that will increase public awareness of financial relationships between drug and device manufacturers and certain health care providers. This is one of many steps under the Affordable Care Act designed to increase transparency in the health care system, which can lead to better care at lower costs.Continue reading
The SBIR/STTR program has not been reauthorized yet but we are one step closer as the December 16th deadline approaches.
Monday (December 12, 2012) word of a Senate/House compromise was announced that may lead to a positive outcome that would reauthorize the SBIR/STTR program for six years. This would be a huge improvement over the multiple short term extensions we have seen in recent years. Continue reading
On Thursday December 8, 2011, the City of Maricopa held its 5th Annual Economic Development Summit. Over 100 attendees were present, representating the development, land investment, business, and real estate sectors as well as local stakeholder group.Continue reading
List Features 100 Privately-Held Companies with Compelling Business Models, Strong Management, Investment Capital and Notable CustomersContinue reading
Estimated at $20B, the Medial Device Tax was included in the Affordable Care Act that was signed into law by President Obama in 2010. The amount is based on a 2.3% excise tax that will be levied on the total revenues of a company, regardless of whether a company generates a profit, starting in 2013.
While many industry groups including AZBio, AdvaMed, and MDMA have been sharing information on why this tax is unwise and have worked to explain the negative effects that it could have on innovation and patient care, there is always the possibility that it will not be repealed before 2013.
Ernst and Young recently published a Tax Note on the Medical Device Tax that gives a comprehensive overview of what it is, who it affects and how they will be affected. The tax note is provided below as published by E&Y and is shared with permission.Continue reading
On Aug. 26, 1976, a time bomb exploded in Yambuku, a remote village in Zaire, (now the Democratic Republic of the Congo). A threadlike virus known as Ebola had emerged, soon earning a grim distinction as one of the most lethal, naturally occurring pathogens on earth, killing up to 90 percent of its victims, and producing a terrifying constellation of symptoms known as hemorrhagic fever.
Now, Charles Arntzen, a researcher at the Biodesign Institute at Arizona State University, along with colleagues from ASU, the University of Arizona College of Medicine-Phoenix, and the United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, have made progress toward a vaccine against the deadly virus. Read more @ ASU Biodesign
Beginning in November 2011, AZBio reached out across Arizona and asked our community to rate the importance of key factors related to the growth of our bioscience industry here in Arizona as well as what areas AZBio should focus on in 2012 on a rating scale from 1 to 5 with 5 being most important.
What do AZ Bioscience companies need to thrive? Of fifteen issues, here are your top five areas based on the number of 4’s and 5’s combined.
Stay Tuned in December for a sneak peek at AZbio’s Plans for 2012.